Direct compression of Qingwen Baidu Powder Veterinary Grade API in veterinary tablet manufacturing begins with size reduction through a cone mill fitted with a 1.0 mm rasp screen at a tip speed not exceeding 15 m/s. The milled powder is sifted on a vibratory sieve; the fraction retained above 180 µm is returned to the mill. Loss on drying is controlled to ≤5.0% by USP <731> at 105°C. A representative direct-compression formulation contains 30.0 wt% Qingwen Baidu Powder, 38.0 wt% microcrystalline cellulose PH102, 25.0 wt% anhydrous lactose DT, 5.0 wt% sodium starch glycolate, 1.0 wt% colloidal silicon dioxide, and 1.0 wt% magnesium stearate. The dry blend is mixed in a 600 L V-shell blender for 18 minutes at 12 rpm after geometric pre-blending. The final blend is compressed on a 27-station rotary tablet press with precompression force 4.0–6.0 kN and main compression force 12.0–18.0 kN. Tablet breaking force is measured by USP <1217> and maintained at 70–110 N; friability is measured by USP <1216> and kept below 1.0%. Disintegration time is tested by USP <701> at 37°C in purified water; a typical acceptance criterion is not more than 30 minutes. Uniformity of dosage units is tested by USP <905> with acceptance value ≤15.0. Tablets are film-coated with 3.0–4.0 wt% aqueous hydroxypropyl methylcellulose-based coating in a perforated pan at inlet air temperature 60–70°C. Coating is required because the uncoated tablet surface is hygroscopic and may darken when exposed to 60% RH for more than 6 hours. If direct-compression blend flow is unacceptable, a wet granulation route is used. Povidone K30 is dissolved in purified water at 5.0 wt% binder concentration, and granulation is carried out in a high-shear mixer with impeller speed 150 rpm and chopper speed 1500 rpm. Wet mass is dried in a fluid-bed dryer with inlet air temperature 65°C until loss on drying is 2.0–3.5%. The granules are passed through a 1.0 mm screen. Granulation time is limited to 3–5 minutes after binder addition because over-granulation reduces disintegration rate. Published data for this specific botanical matrix is limited, so each batch requires a compression profile trial.

What Limits Sterile Filtration Throughput for Injectable Fractions?

The injectable route for Qingwen Baidu Powder Veterinary Grade API is restricted to purified extracts, not the unrefined powder. Aqueous decoction is prepared under reflux at 95–100°C for 60–90 minutes and clarified through a disk-stack centrifuge at 8000 rpm. The supernatant is concentrated under vacuum at 50–60°C and passed through a 0.45 µm polyethersulfone membrane before sterile filtration. Sterile filtration is performed with a 0.22 µm polyvinylidene fluoride cartridge; throughput is limited by pectin-like polysaccharide content and turbidity. Prefiltration with diatomaceous earth is avoided because extractable silicates may contaminate the final injectable. The filtered solution is filled into Type I glass vials under Grade A laminar flow. Terminal sterilization is preferred when solution stability permits. A validated cycle at 121°C for 15 minutes with steam-air mixture is used for heat-stable formulations. For heat-labile formulations, aseptic filling through a sterilizing-grade 0.22 µm filter is mandatory. Bacterial endotoxins are tested by USP <85>; the limit is calculated from the maximum dose per kg body weight, often not more than 0.5 EU/mL for small-volume injectables. Sterility is tested by USP <71> membrane filtration. Residual solvents are addressed under VICH GL18. The pH is held at 5.5–7.0 with citrate buffer; phenolic components may precipitate below pH 4.5 and oxidize above pH 8.0. Dissolved oxygen is reduced by nitrogen sparging to less than 0.5 ppm. Stainless steel 316L contact surfaces are used because iron leaching accelerates color formation. Subvisible particulate matter is controlled by USP <788>. The terminal injectable is a clear or slightly opalescent liquid. Use of unrefined powder for injection is not permitted; only the purified extract fraction is suitable for sterile processing.

Capsule Filling and Powder Rivulet Control in Dosator Machines

Dosator-type capsule machines impose narrow requirements on powder bed uniformity. The powder is pre-dried to a loss on drying of ≤4.0% by USP <731> at 105°C. The dried powder is milled through a 0.8 mm screen. The capsule blend is prepared with 45.0 wt% Qingwen Baidu Powder, 48.5 wt% spray-dried lactose, 5.0 wt% crospovidone, 0.5 wt% colloidal silicon dioxide, and 1.0 wt% magnesium stearate. The blend is mixed in a bin blender for 15 minutes at 10 rpm. Flow properties are checked before encapsulation; target Carr Index is ≤25.0 and Hausner ratio is ≤1.25. Powder fill weight is set on an automatic dosator encapsulation machine with pin diameter adjusted to achieve target fill weight of 350–400 mg in a size 0 capsule. Fill weight variation is monitored every 15 minutes. Capsule shells are stored at 20–25°C and 35–45% RH to prevent brittleness. Gelatin shell cross-linking may occur if the powder moisture content exceeds 6.0% or if aldehyde impurities are present; HPMC shells are used when this risk is identified. Disintegration of the filled capsules is tested by USP <701> at 37°C with a not more than 30 minutes acceptance criterion. Content uniformity is tested by USP <905> with acceptance value ≤15.0. Microbiological limits are tested by USP <61> and USP <62>; total aerobic microbial count is controlled to not more than 10³ CFU/g and combined yeast/mold count to not more than 10² CFU/g. Powder-bed rivulet formation is reduced by maintaining filling-room relative humidity below 45%. Published batch-to-batch variance data for this specific botanical capsule formulation is limited, so encapsulation speed is ramped from 50% to 80% of maximum machine speed only after fill weight variation passes an in-process run of 120 capsules.

Because sachet filling demands stable bulk density and minimal segregation, Qingwen Baidu Powder for oral granules is wet-granulated with a spray-dried vehicle before packaging. The granulation fluid is purified water containing 3.0 wt% povidone K30, sprayed at 60–80 g/min into a fluid-bed granulator with inlet air temperature 70°C. Granule growth is controlled to a D50 of 150–250 µm and D90 of 420–500 µm. The dried granules are passed through a 1.25 mm screen. Loss on drying is held at 2.0–3.0% by USP <731>. Bulk density is measured by USP <616> Method I; the target is 0.45–0.60 g/mL. Tapped density is measured after 1250 taps; the Hausner ratio is controlled at ≤1.25. Sachet filling is performed on a vertical form-fill-seal machine with an auger filler. Fill weight variation is maintained at ±5.0% of target. The film laminate is polyester/aluminum foil/polyethylene with oxygen transmission rate less than 1.0 cm³/m²/24 h at 23°C and 0% RH. A desiccant sachet is inserted when fill weight exceeds 10 g. For oral suspension reconstitution, the granules are dispersed in 100 mL water at 25°C with manual shaking for 30 seconds. Sedimentation volume is evaluated after 2 hours; a value not less than 0.8 is targeted. Published data for this specific configuration is limited, so the sedimentation ratio is verified batch-wise. The oral powder product is a pale brown granule with characteristic odor; odor modifiers are avoided in medicated formulations because they can alter palatability in target species. The powder is packaged in sealed sachets to block moisture uptake above 60% RH. If bulk density drops below 0.40 g/mL, auger fill weight variation exceeds ±5.0%. Therefore, the granulation endpoint is controlled by both loss on drying and bulk density, not by time alone.

When Qingwen Baidu Powder Is Incorporated into a Medicated Feed Premix

Premix manufacturing begins with geometric dilution of the powder into a dry carrier. A Type A medicated article is produced by mixing Qingwen Baidu Powder with calcium carbonate or ground rice hulls in a double-ribbon mixer. The first dilution step is 1 part powder to 9 parts carrier; the blend is mixed for 20 minutes at 50% mixer working capacity. The second dilution is 1 part preblend to 9 parts carrier, again mixed for 20 minutes. The final inclusion rate is based on the intended daily intake of the target species. The coefficient of variation for active-marker distribution is tested by sampling 10 points with a grain thief and analyzing by a validated HPLC or spectrophotometric method. The acceptance criterion is CV ≤5.0%. A CV above 10.0% requires longer mixing time or a smaller carrier particle size. Particle size of the finished premix is controlled with a sieve stack; D90 is typically ≤500 µm and the fraction below 75 µm is kept below 20.0% to limit dusting. The mixer is equipped with a dust collector; air velocity at the pickup point is maintained at 0.5–1.0 m/s. Carryover between batches is controlled by flushing with ground corn; swab samples from mixer surfaces are collected and analyzed for marker residue. 21 CFR 225.1 requires medicated feed facilities to maintain written procedures for equipment cleaning and batch records. The premix is packaged in multi-wall paper bags with a polyethylene liner; each bag is labeled with the active concentration in g/kg. The premix should not be stored above 30°C or above 60% RH. Open storage near molasses-based feeds or acid salts leads to moisture uptake and caking within 24 hours. When the premix is mixed into final feed at 0.5–5.0 kg/t, the final mixer must be validated for homogeneity. A horizontal ribbon mixer with a mixing time of 10–15 minutes at 70% capacity is common. Incompatibility with feed enzymes is not systematically documented; published data for this botanical matrix in feed enzyme combinations is limited. The finished feed should be sampled at the discharge point and analyzed for marker content. Therapeutic consistency is not determined solely by label claim; it relies on blend homogeneity and moisture control.

Oral Solutions Require Preservative, pH, and Solubilization Management

Aqueous oral vehicles containing Qingwen Baidu Powder are formulated either as solutions or suspensions for drench or drinking water administration. The insoluble fraction is suspended with 0.1–0.3 wt% xanthan gum; sodium carboxymethylcellulose is an alternative thickener at 0.3 wt%. Polysorbate 80 is added at 0.2–0.5 wt% and dispersed in purified water at 35–40°C. Sodium benzoate is added at 0.1–0.2 wt% as preservative; potassium sorbate at 0.1 wt% is used when pH is below 5.5. Citric acid monohydrate is added to adjust pH to 5.0–6.0. The liquid is homogenized in a high-shear rotor-stator mixer at 3000 rpm for 15 minutes and then passed through a colloid mill with gap setting 150–200 µm. The resulting suspension is filled into amber PET bottles with child-resistant caps. Antimicrobial effectiveness is tested by USP <51> using specified challenge organisms. pH is measured by USP <791>. Viscosity is measured by USP <911>; the target is 50–200 mPa·s at 25°C. If viscosity exceeds 250 mPa·s, proportioner pump delivery may be inaccurate. The target wetting time is less than 60 seconds in 1 L of water at 25°C. If the suspension flocculates, sodium citrate is added at 0.1 wt% to chelate trace metals. Stainless steel 316L is required for all contact surfaces; iron, copper, and aluminum accelerate oxidative browning. The product is protected from light; amber PET bottles limit UV exposure. Long-term storage at 25°C/60% RH in a stability chamber is conducted per VICH GL3. The terminal product appears as a pale yellow to brown suspension with a characteristic botanical odor. After 24 hours, the sediment should redisperse with 10 manual inversions. Published data for this specific configuration is limited, so the redispersion criterion is established during development. Antifoam agents are avoided unless foam height exceeds 10 mL; simethicone emulsion at 0.01 wt% may be added if foaming interferes with filling. The oral liquid is dosed by a calibrated drench gun or proportioner pump; dose accuracy depends on viscosity and suspended-solids uniformity.